Movatterモバイル変換


[0]ホーム

URL:


CA1315689C - Quarternary derivatives of noroxymorphone which relieve nausea and emesis - Google Patents

Quarternary derivatives of noroxymorphone which relieve nausea and emesis

Info

Publication number
CA1315689C
CA1315689CCA000548964ACA548964ACA1315689CCA 1315689 CCA1315689 CCA 1315689CCA 000548964 ACA000548964 ACA 000548964ACA 548964 ACA548964 ACA 548964ACA 1315689 CCA1315689 CCA 1315689C
Authority
CA
Canada
Prior art keywords
administration
noroxymorphone
narcotic analgesic
morphine
emesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA000548964A
Other languages
French (fr)
Inventor
Leon I. Goldberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Chicago
Original Assignee
University of Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/092,470external-prioritypatent/US4861781A/en
Application filed by University of ChicagofiledCriticalUniversity of Chicago
Application grantedgrantedCritical
Publication of CA1315689CpublicationCriticalpatent/CA1315689C/en
Anticipated expirationlegal-statusCritical
Expired - Lifetimelegal-statusCriticalCurrent

Links

Classifications

Landscapes

Abstract

QUATERNARY DERIVATIVES OF NOROXYMORPHONE
WHICH RELIEVE NAUSEA AND EMESIS

ABSTRACT OF THE DISCLOSURE

Quaternary derivatives of noroxymorphone are used to prevent or relieve nausea and emesis associated with the use of narcotic analgesics without interfering with the analgesic activity of the drugs. A particularly preferred compound is methylnaltrexone. The compound is administered in a concentration between 0.05 mg/kg and 1.0 mg/kg prior to or concurrently with the administration of the narcotic analgesic.

Description

~3~ 3 ~0355--99 OUATERNARY DERIVATIVES OF NOROXYMORPHO
~HICH RELIEVE NAUSEA AND EMESIS
The administration of therapeutic doses of morphine and other clinically useful narcotie analgesies is often aecompanied by unpleasant side effects on the gas-tro-intestinal system. For instance, morphine and related opiates such as meperidine and methadone may reta~d intestinal mobility by causing con-traetions of -the small bowel eireular smooth musele.

Morphine and related narcoties may also induce nausea and increased mobility of the gastro-intes-tinal tract resulting in emesis or vomiting~ These side effects are eaused by direet stimulation of the chemoreeeptor trigger zone for emesis in the area postrema of the medulla. (Goodman and Bilman, The Pharmaeologieal Basis of Theraneu~ics, p. 502 [6`th ed. 1980]). Studies have shown that morphine and other nareoties eause emesis in dogs. For example, Wang and Glaviano, JPET 111:329-334 ~9143~, reported that administration of 0.5 mg/kg of morphine intravenously to 12 dogs resulted in emesis in 9 dogs within an average of 2.
minutes. (Mg/kg refers to milligrams of morphine per kilograms of body weight.) When 1.0 mg/kg of ~ ~.

, . . '. ' :
.
.
. .

.

1 morphine was administered intramuscularly to 13 dogs, 12 of them vomited within an average time of 3.5 minutes.

U. S. Patent No. 4,176,186 to myself and others disclosed treatment of intestinal immobility associated with the use of narcotic analgesics through the administration of guaternary derivatives of noroxymorphone.'' It has now been discovered that the same compounds are also useful fox the treatment, ~oth prophylactic.and therapeutic,'of the nausea and vomiting associated with the administration of these drugs.
'~'According to the invention, therefore, nausea and vomiting by warm-blooded animals receiving morphine and lS related opiates~ meperidine,-methadone or the like, may be prevented ~r relieved by the administration of methylnaltrexone or other quaternary derivatives of noroxymorphone represented by the formula:
rA/~ C~13 X

` ~`b wherein ~/0 R is allyl or a related radical such as chloroallyl, cyclopropyl-methyl Gr propargyl, and X is the anion of an acid, especially a chloride, bromide, iodide or methylsulfate anion.
These compounds are administered to the animal either prior to or . simultaneously with the administration of the narcotic analgesic. They may be ~3~
-- 3 ~
admini~-tered either enterally or paren-terally. There has no-t been observed any interference with the analgesic activi-ty of the opi~tes.

As used herein, unless the sense of the usage indicates otherwise, the term l'morphine" refers to any narcotic analgesic.

This invention relates to the use of quaternary derivatives of noroxymorphone to prev~nt or relieve nausea and vomiting associated with the administration of morphine to warm-blooded animals. The useful compounds are represented by the formula:
R X
I ~ CH3 r- N

wherein R is allyl or a related radical such as chloroallyl, cyclopropyl-methyl or propargyl, and X is the anion of an acid, especially a chloride, bromide, iodide or methylsulfate anion.
!
The compounds are synthesized as described in United 5tates Patent No. 4,176,I86. A particularly preferred noroxymorphone derivative is methylnaltrexone, but other compounds represented by the above formula are also suitable.
Methylnaltrexone or other noroxymorphone deriva-tives may be administered to the patient either -? ~: 1 '`' ~

' ., ~ . .. .
. . .
,: ~ , . ' "; ' ' , ~ ' ' ' ' " ', ' ' ' ' ' ':
'" ' : : ' ~ :- ~' . ' :

~3~LS~

1 enterally or parenterally. However, a preferred method of administration is by injection. Nausea and emesis may follow after even a single does sf morphine, unlikP
intestinal immobility which is usually the effect of chronic repeated usage of the drug. Consequently, it is contemplated that-the patient will be given an injection of methylnaltrexone prior to surgery or other occasion when morphine is used to treat acute pain.
As illustrated :-by :~he ~ifollowing Controls and Examples, our studies show that methylnaltrexone inhibits emesis when administered either together with the morphine or before the morphine is administered. It is thought that methylnaltrexone- or other quaternary noroxymorphone derivatives may be administered up to two hours before the administration of morphine, but that period may be variable. In our studies, methylnaltrexone was administered intramuscularly by means of a syringé. Methylnaltrexone may also be administered enteraIly or parenterally by other means.
It has been found to be effective in dosages in the range of about 0.05 mg/kg to about 1.0 mg~kg for each 1 mg/kg of administered morphine. It was found effective when administered in the same syringe as morphine and also when administered up to about one hour before the administration of morphine.
The effect of methylnaltrexone in reversing the emetic effects of morphine is illustrated herein. The unit of mg/kg refers to milligrams of substance administered per kilograms of body weight.

. ~ CONTROL 1 AND EXAMPLE_1 one mg/kg of morphine was administered intramuscularly to five dogs. Four dogs vomited. In each instance, vomiting occurred within four minutes.
On a different day the same dose of morphine was ~3~5~

1 administered intramuscularly to the same five dogs in the same syringe with 1 mg/kg of methylnaltrexone. None of the dogs vomited.

Six dogs were given intramuscular doses of 1 mg/kg of morphine. All six dogs vomited. On an ~dditional day the same dose of morphine was combined with 0.5 mg/kg of methylnaltraxone and administered in the same syringe to the same dogs. None of the dogs vomited.

one mg/kg of morphine was administered intramuscularly to three dogs. All three dogs vomited.
On an additional day the morphine was combined with 0.25 mg/kg of methylnaltrexone and administered in the same syringe. None of the dogs vomited.

Methylnaltrexone was administered to two dogs prior to the administration of 1 mg/kg morphine. In one dog, 0.5 mg/kg of methylnaltrexone was administered intramuscularly 15 minutes before the morphine. No vomiting occurred. In the second dog, the same dose o~
methylnal~rexone was administered 30 minutes before the administration of morphine. No vomiting occurred.

O. 05 mg/kg methylnaltrexone was administered intravenously to four dogs one minute prior to the administration of 1.0 mg/kg morphine. No vomiting occurred in any of the dogs. On a different day, the same animals were given 1.0 mg/kg morphine without the administration of methylnaltrexone. All four dogs 3 5 vomited .

~3~6t~

The administration of methylnaltrexone alone was found to produce no noticeable effec-ts in the animals. Previous studies with larger doses of methylnaltrexone have demonstrated that unlike the non-quaternary naltrexone, methylnaltrexone does no-t precipitate withdrawal systems in morphine-tolerant dogs. Russell et al., Eur~ J. Pharmacol.
78:255-261 ~19823. Methylnaltrexone has not been found -to interfere with the analgesic activity of morphine or narcotics.

, . :

Claims (19)

CA000548964A1987-09-031987-10-09Quarternary derivatives of noroxymorphone which relieve nausea and emesisExpired - LifetimeCA1315689C (en)

Applications Claiming Priority (2)

Application NumberPriority DateFiling DateTitle
US07/092,470US4861781A (en)1986-03-071987-09-03Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US092,4701987-09-03

Publications (1)

Publication NumberPublication Date
CA1315689Ctrue CA1315689C (en)1993-04-06

Family

ID=22233375

Family Applications (1)

Application NumberTitlePriority DateFiling Date
CA000548964AExpired - LifetimeCA1315689C (en)1987-09-031987-10-09Quarternary derivatives of noroxymorphone which relieve nausea and emesis

Country Status (6)

CountryLink
JP (1)JP2625457B2 (en)
KR (1)KR890004704A (en)
CA (1)CA1315689C (en)
DK (1)DK167340B1 (en)
NZ (1)NZ222911A (en)
PH (1)PH22582A (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US7563899B2 (en)2005-05-252009-07-21Progenics Pharmaceuticals, Inc.(S)-N-methylnaltrexone
US7674904B2 (en)2005-05-252010-03-09Progenics Pharmaceuticals, Inc.Synthesis of R-N-methylnaltrexone
US8247425B2 (en)2008-09-302012-08-21WyethPeripheral opioid receptor antagonists and uses thereof
US8338446B2 (en)2007-03-292012-12-25Wyeth LlcPeripheral opioid receptor antagonists and uses thereof
US8471022B2 (en)2008-02-062013-06-25Progenics Pharmaceuticals, Inc.Preparation and use of (R),(R)-2,2′-bis-methylnaltrexone
US8518962B2 (en)2005-03-072013-08-27The University Of ChicagoUse of opioid antagonists
US8524731B2 (en)2005-03-072013-09-03The University Of ChicagoUse of opioid antagonists to attenuate endothelial cell proliferation and migration
US8546418B2 (en)2007-03-292013-10-01Progenics Pharmaceuticals, Inc.Peripheral opioid receptor antagonists and uses thereof
US8552025B2 (en)2003-04-082013-10-08Progenics Pharmaceuticals, Inc.Stable methylnaltrexone preparation
US8685995B2 (en)2008-03-212014-04-01The University Of ChicagoTreatment with opioid antagonists and mTOR inhibitors
US9102680B2 (en)2007-03-292015-08-11Wyeth LlcCrystal forms of (R)-N-methylnaltrexone bromide and uses thereof
US12303592B2 (en)2006-08-042025-05-20Wyeth, LlcFormulations for parenteral delivery of compounds and uses thereof

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US6274591B1 (en)1997-11-032001-08-14Joseph F. FossUse of methylnaltrexone and related compounds
US6451806B2 (en)1999-09-292002-09-17Adolor CorporationMethods and compositions involving opioids and antagonists thereof
US6469030B2 (en)1999-11-292002-10-22Adolor CorporationMethods for the treatment and prevention of ileus
US9662325B2 (en)2005-03-072017-05-30The University Of ChicagoUse of opioid antagonists to attenuate endothelial cell proliferation and migration
EP1861096B1 (en)2005-03-072018-12-26The University of ChicagoUse of opioid antagonists to attenuate endothelial cell proliferation and migration
WO2007043518A1 (en)*2005-10-112007-04-19Toray Industries, Inc.Therapeutic agent for nausea and/or vomiting
JP5581211B2 (en)*2007-08-092014-08-27レンセラール ポリテクニック インスティチュート Quaternary opioid carboxamide

Cited By (30)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US8552025B2 (en)2003-04-082013-10-08Progenics Pharmaceuticals, Inc.Stable methylnaltrexone preparation
US9669096B2 (en)2003-04-082017-06-06Progenics Pharmaceuticals, Inc.Stable pharmaceutical formulations of methylnaltrexone
US10376584B2 (en)2003-04-082019-08-13Progenics Pharmaceuticals, Inc.Stable pharmaceutical formulations of methylnaltrexone
US8524731B2 (en)2005-03-072013-09-03The University Of ChicagoUse of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en)2005-03-072013-08-27The University Of ChicagoUse of opioid antagonists
US8343992B2 (en)2005-05-252013-01-01Progenics Pharmaceuticals, Inc.Synthesis of R-N-methylnaltrexone
US7674904B2 (en)2005-05-252010-03-09Progenics Pharmaceuticals, Inc.Synthesis of R-N-methylnaltrexone
US7563899B2 (en)2005-05-252009-07-21Progenics Pharmaceuticals, Inc.(S)-N-methylnaltrexone
US8916581B2 (en)2005-05-252014-12-23Progenics Pharmaceuticals, Inc.(S)-N-methylnaltrexone
US9597327B2 (en)2005-05-252017-03-21Progenics Pharmaceuticals, Inc.Synthesis of (R)-N-methylnaltrexone
US8003794B2 (en)2005-05-252011-08-23Progenics Pharmaceuticals, Inc.(S)-N-methylnaltrexone
US12303592B2 (en)2006-08-042025-05-20Wyeth, LlcFormulations for parenteral delivery of compounds and uses thereof
US8853232B2 (en)2007-03-292014-10-07Wyeth LlcPeripheral opioid receptor antagonists and uses thereof
US8772310B2 (en)2007-03-292014-07-08Wyeth LlcPeripheral opioid receptor antagonists and uses thereof
US8546418B2 (en)2007-03-292013-10-01Progenics Pharmaceuticals, Inc.Peripheral opioid receptor antagonists and uses thereof
US8338446B2 (en)2007-03-292012-12-25Wyeth LlcPeripheral opioid receptor antagonists and uses thereof
US9102680B2 (en)2007-03-292015-08-11Wyeth LlcCrystal forms of (R)-N-methylnaltrexone bromide and uses thereof
US9879024B2 (en)2007-03-292018-01-30Progenics Pharmaceuticals., Inc.Crystal forms of (R)-N-methylnaltrexone bromide and uses thereof
US8916706B2 (en)2008-02-062014-12-23Progenics Pharmaceuticals, Inc.Preparation and use of (R),(R)-2,2′-bis-methylnaltrexone
US8471022B2 (en)2008-02-062013-06-25Progenics Pharmaceuticals, Inc.Preparation and use of (R),(R)-2,2′-bis-methylnaltrexone
US8685995B2 (en)2008-03-212014-04-01The University Of ChicagoTreatment with opioid antagonists and mTOR inhibitors
US10383869B2 (en)2008-03-212019-08-20The University Of ChicagoTreatment with opioid antagonists and mTOR inhibitors
US9526723B2 (en)2008-03-212016-12-27The University Of ChicagoTreatment with opioid antagonists and mTOR inhibitors
US8455644B2 (en)2008-09-302013-06-04WyethPeripheral opioid receptor antagonists and uses thereof
US9492445B2 (en)2008-09-302016-11-15Wyeth, LlcPeripheral opioid receptor antagonists and uses thereof
US9724343B2 (en)2008-09-302017-08-08Wyeth, LlcPeripheral opioid receptor antagonists and uses thereof
US9180125B2 (en)2008-09-302015-11-10Wyeth, LlcPeripheral opioid receptor antagonists and uses thereof
US8822490B2 (en)2008-09-302014-09-02Wyeth LlcPeripheral opioid receptor antagonists and uses thereof
US8420663B2 (en)2008-09-302013-04-16WyethPeripheral opioid receptor antagonists and uses thereof
US8247425B2 (en)2008-09-302012-08-21WyethPeripheral opioid receptor antagonists and uses thereof

Also Published As

Publication numberPublication date
KR890004704A (en)1989-05-09
DK693387D0 (en)1987-12-30
JPS6468376A (en)1989-03-14
PH22582A (en)1988-10-17
DK693387A (en)1989-03-04
JP2625457B2 (en)1997-07-02
NZ222911A (en)1990-11-27
DK167340B1 (en)1993-10-18

Similar Documents

PublicationPublication DateTitle
US4861781A (en)Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US4719215A (en)Quaternary derivatives of noroxymorphone which relieve nausea and emesis
CA1315689C (en)Quarternary derivatives of noroxymorphone which relieve nausea and emesis
EP0306575B1 (en)Quaternary derivatives of noroxymorphone which relieve nausea and emesis
DE69233169T2 (en) Composition containing cisplatin and topotecan as an anti-tumor.
DE69634609T2 (en) ANALGESIS SYNERGY BY SIMULTANEOUS ADMINISTRATION OF SUBANALGESIC CANS OF A MU-OPIOID AGONIST AND A KAPPA-2-OPIOI AGONIST
CA1200501A (en)Nalbuphine - narcotic analgesic composition and method of producing analgesia
PT1096936E (en)Treatment of dyskinesia through mu selective opioid antagonists
EP0514023B1 (en)Use of glycine/NMDA receptor ligands for the manufacture of a medicament for the treatment of drug dependence and withdrawal
US5935944A (en)Formulation for I.V. administration of the boron delivery drug, boronophenylalanine (BPA)
AU684711B2 (en)Use of 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine for the treatment of pain and oedema
LT3449B (en)New use of ropivacaine
Dubois et al.Prevention and treatment of the gastric symptoms of radiation sickness
US4829068A (en)Treatment of disorders of the gastro-intestinal tract
KR930702985A (en) Treatment of Esophageal Cancer
US4575506A (en)Method of treatment for inhibiting the tolerance onset while treating painful syndromes with central analgesics
US9192602B2 (en)Indication of anthra[2,1,c][1,2,5]thiadiazole-6,11-dione compound in alleviating pain
GB2189703A (en)Vinpocetine
Culpepper-Morgan et al.Narcotic Induced Constipation: Dose Response
DE69816790T2 (en) IMPROVING OPIOID TOLERANCE BY INHIBITING THE INDUCIBLE NITROGEN OXIDE SYNTHASE FOR TREATING PAIN
US20090270401A1 (en)Use of a dihydroimidazopyrazoine derivative for treating or preventing pain
CA2295429A1 (en)Treatment or prevention of diarrhea
Acri et al.Characterization of the Discriminative Stimulus Effects of Benztropine, A Potential Cocaine Therapeutic Agent
Genis et al.Comments on Pentland and Donald
Lippmann et al.Analgesic onset time of iv butorphanol in postsurgical patients

Legal Events

DateCodeTitleDescription
MKEXExpiry

[8]ページ先頭

©2009-2025 Movatter.jp